smartbax raises €4.7M Series A round
22 October 2025· Munich, Germany· health, pharma, biotech, b2b, deep_hardware
The funding will be used to progress smartbax's proprietary pipeline of small-molecule antibiotics, specifically advancing its lead inhibitor through preclinical development and developing enzymatic activators that induce bacterial self-digestion
Investors
LeadAnobis Asset
Also participating
High-Tech GründerfondsBayern KapitalUnternehmerTUM Funding for InnovatorsBoehringer Ingelheim Venture Fund
About smartbax
Stage
Series A
Headquarters
Munich, Germany
Founded
2021
Team Size
6–20
Sectors
healthpharmabiotechb2bdeep_hardware